MENU

SRPT Stock Sarepta Therapeutics (SRPT, $40.05) Moving Average Convergence Divergence (MACD) Histogram turned positive on May 21, 2025

A.I.dvisor
at Tickeron.com
Loading...
SRPT - Sarepta Therapeutics
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $40.05
Daily change: +$0.06 (+0.15%)
Daily volume: 8.4M
Capitalization: $3.9B
Industry: Biotechnology
This is a Bullish indicator signaling SRPT's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 50 similar cases where SRPT's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

SRPT's RSI Indicator ascends from oversold territory

The RSI Oscillator for SRPT moved out of oversold territory on May 20, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In of the 36 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 60 cases where SRPT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on May 21, 2025. You may want to consider a long position or call options on SRPT as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SRPT just turned positive on May 21, 2025. Looking at past instances where SRPT's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SRPT advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

SRPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRPT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.373) is normal, around the industry mean (16.080). P/E Ratio (27.205) is within average values for comparable stocks, (59.383). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.197). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (1.909) is also within normal values, averaging (268.270).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SRPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of treatments for life-threatening illnesses and viruses

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
215 First Street
Phone
+1 617 274-4000
Employees
1314
Web
https://www.sarepta.com